Stemedica Cell Technologies

About Stemedica Cell Technologies

Stemedica Cell Technologies is a biotechnology company specializing in the development and manufacturing of allogeneic progenitor cell products for the treatment of ischemic stroke and spinal cord injury. The company operates in the regenerative medicine market, serving patients and healthcare providers seeking advanced therapeutic solutions. Stemedica's business model revolves around its proprietary manufacturing technology platform, which produces ischemia tolerant mesenchymal stem cells (itMSCs) and ischemia tolerant neural progenitor cells (itNSCs) under a low oxygen, low tension environment in a cGMP compliant facility. These products are currently in clinical development, with the lead drug candidate, itMSCs, undergoing Phase IIb/III clinical trials for chronic ischemic stroke. The company generates revenue through the development, licensing, and potential commercialization of its cell therapy products. Stemedica's team comprises experienced scientists, management, and technicians dedicated to advancing their proprietary technology.